Phase 2
Completed N=301
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Source: ClinicalTrials.gov NCT01591044 ↗Enrolled (actual)
301
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcomePrimary: Change in FEV1 — -0.40; 0.69; -0.59 percentage of change
Summary
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in FEV1 |
-0.40; 0.69; -0.59 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical history of asthma
- Ability to perform spirometry
Exclusion Criteria
- Chronic obstructive pulmonary disease or bronchiectasis
- Upper or lower respiratory infection
Data sourced from ClinicalTrials.gov (NCT01591044). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.